Cutaneous Leishmaniasis (CL) is a painful disease that exerts a serious toll on societies around the world that are afflicted by it. Although not life-threatening, the skin ulcers and scars it causes can lead to isolation and psychosocial pathologies due to social stigma, and its occurrence is often associated with regional conflicts. The Cutaneous Leishmaniasis Research Meeting was held on December 7, 2020, with participation by basic researchers, clinical researchers, and drug discovery experts involved in research and development related to CL under the auspices of the Joint Usage/Research Center on Tropical Disease, Institute of Tropical Medicine. In addition, the CL Webinar was held on March 5, 2021, hosted by the Graduate School of Tropical Medicine and Global Health, co-hosted by the Institute of Tropical Medicine, and supported by Médecins Sans Frontières and DNDi.
On this occasion, together with publishing the proceedings of the CL Research Meeting and the CL Webinar, the webinar video and summaries are made available online to the public. In the webinar, international experts shared the latest information regarding the impact of CL on maternal and child health, mental health, humanitarian aid in conflict situations, as well as research and development into badly needed new treatments and vaccines. We hope this information will act as a valuable source of information on recent developments in CL within the field of global health.
Research Meeting and Webinar on Cutaneous Leishmaniasis (CL):Research and development for neglected diseases and associated social issues
※Click on the title to open a PDF file with a summary of each lecture.
Agenda & profile
巻頭言：Haruki Yamada, Kiyoshi Kita
Part 1 Cutaneous Leishmaniasis (CL) Research Meeting
Cutaneous Leishmaniasis: Current situation and DNDi’s approach: Byron Arana
Preclinical development of CpG D35 for combined treatment of cutaneous leishmaniasis: Ken J. Ishii
Prospects for new treatments for leishmaniasis: Charles Mowbray
CL Treatment Strategy: The vision and pathway to access: Olawale Ajose
A live attenuated markerless prophylactic vaccine for leishmaniasis using CRISPR gene editing: Shinjiro Hamano
Part 2 Webinar: Cutaneous Leishmaniasis (CL)
Cutaneous Leishmaniasis in conflict situations: Koert Ritmeijer
Cutaneous leishmaniasis and mental health: Exploring psychosocial impact and CL-associated stigma (the ECLIPSE programme): Lisa Dikomitis，Helen Price，et al．
Cutaneous Leishmaniasis (CL) in women and children: Issam Bennis
Cutaneous Leishmaniasis: Current treatments and gaps: Byron Arana
Current approaches to the development of a vaccine against CL: Yasuyuki Goto
